Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pulmonary Hypertension
100%
Sildenafil Citrate
100%
Pediatric Hypertension
100%
Therapeutic Applications
100%
Nitric Oxide
33%
Pediatric Population
33%
Sildenafil
33%
Phosphodiesterase Type 5 Inhibitors
33%
Highly Selective
16%
Neonate
16%
Poor Prognosis
16%
Current Treatment
16%
Treatment Modalities
16%
Lung Disease
16%
Vasodilator
16%
Randomized Controlled Study
16%
Cyclic GMP
16%
Pharmacological Therapy
16%
Selective Inhibitor
16%
Safety Efficacy
16%
Endothelial Function
16%
Endothelial Dysfunction
16%
Supportive Therapy
16%
Prostacyclin
16%
Pulmonary Vascular Resistance
16%
Systemic Side Effects
16%
Clinical Case Reports
16%
Pulmonary Vasculature
16%
Exhaled Nitric Oxide
16%
Medial Hypertrophy
16%
Persistent Pulmonary Hypertension of the Newborn
16%
Experimental Drugs
16%
Idiopathic Pulmonary Arterial Hypertension
16%
Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
16%
Difficult-to-wean
16%
Vasoconstrictor
16%
Endothelin 1 (ET-1)
16%
Postoperative Pulmonary Hypertension
16%
Pulmonary Vasodilation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
100%
Sildenafil
100%
Nitric Oxide
33%
Pharmacotherapy
11%
Endothelin 1
11%
Lung Disease
11%
Prostacyclin
11%
Congenital Heart Disease
11%
Endothelial Dysfunction
11%
Cyclic GMP
11%
Phosphodiesterase V Inhibitor
11%
Phosphodiesterase V
11%
Persistent Pulmonary Hypertension
11%
Adverse Effect
11%